Lobe Sciences Ltd. (LOBE.CN)
| Previous Close | 0.0200 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 32,934 |
| Market Cap | 3.431M |
| Beta (5Y Monthly) | 2.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings Date | Jul 26, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireLobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
VANCOUVER, British Columbia & STUART, Fla., October 02, 2024--Lobe Sciences, Ltd. ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma ("Alera or Alera Pharma"), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent number 12,102,616 titled "Psilocin Mucate". As previously announced, Lobe Sciences will assign t
Business WireLobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
VANCOUVER, British Columbia, August 16, 2024--Lobe Sciences, Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat diseases with unmet medical needs, today announced that is has formed a wholly owned U.S. subsidiary named Alera Pharma, Inc. (Alera). Alera will be assigned the intellectual property rights focused on the Company’s neurological assets and its new chemical entity Psilocin Mucate.
Business WireLobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
VANCOUVER, British Columbia, August 12, 2024--Lobe Sciences Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat diseases with unmet medical needs, today announced that a new board of directors ("Board") has been elected at the Company’s annual general meeting, with shareholders electing the three previously announced nominees: Dr. Frederick D. Sancilio, Dr. Harry Jacobson and Mr. Wesley Ramjeet. Lobe Sciences als
